Hutchmed registers first-in-human trial of ADC HMPL-A830 in tumors
The Phase 1/2 study joins a field of 88 antibody-drug conjugate trials already running in tumors, testing dose and safety before any efficacy signal is due.
Executive Summary
- Hutchmed has registered a Phase 1/2 first-in-human trial for its antibody-drug conjugate in patients with advanced tumors who have exhausted standard treatment, formalizing a new clinical-stage asset.
- The study is open-label and non-randomized, structured to find a tolerable dose and establish early tumor-response signals rather than to support approval on its own.
- The antibody-drug conjugate modality is already extensively represented in tumors, with dozens of programs from major sponsors testing different targets, so this entry competes on execution and eventual target differentiation rather than modality novelty.
- Hutchmed's track record across its broader trial portfolio supports operational execution, though the new trial's protracted timeline pushes any read on the asset's viability well into the future.
The registration
Hutchmed has registered NCT07718581, a Phase 1/2 trial evaluating HMPL-A830, an antibody-drug conjugate, in patients with histologically confirmed, unresectable, advanced or metastatic tumors who have progressed on standard treatment. The study is described as a first-in-human, multicenter, open-label trial, structured to find a tolerable dose ahead of any efficacy claim. It is listed as Not yet recruiting, with a planned start date of August 15, 2026, and enrollment across sites in China. NCT07718581+1HMPL-A830 in Solid TumorsNCT07718581Hutchmed Registers Phase 1/2 Trial of HMPL-A830 in Solid TumorsJul 22, 2026
The design
The trial plans to enroll approximately 147 participants in a non-randomized, open-label, two-arm design with no masking. Its primary outcomes are dose-limiting toxicities, objective response rate by RECIST 1.1, treatment-emergent adverse events, and identification of a recommended Phase 2 or Phase 3 dose, tracked over roughly 12 to 24 months depending on the measure. Secondary endpoints add pharmacokinetic characterization, anti-drug antibody incidence, disease control rate, and progression-free survival over approximately two years. The primary completion date is set for June 26, 2028, with full trial completion anticipated by November 26, 2028. NCT07718581HMPL-A830 in Solid TumorsNCT07718581
The competitive field
Antibody-drug conjugates are a heavily used modality in tumors: 88 trials in the indication have already tested this modality. Named programs in the same modality and indication family include Merck's ifinatamab deruxtecan and AbbVie's telisotuzumab adizutecan, both antibody-drug conjugates in Phase 1/2 and Phase 2 -tumor trials targeting CD276 and MET respectively, and DualityBio's DB-1311, targeting B7H3. HMPL-A830's own target is not established in the trial record, which means its differentiation from these programs cannot yet be assessed on a target basis; the trial competes for now on modality precedent rather than a distinct mechanistic hypothesis. NCT07718581HMPL-A830 in Solid TumorsNCT07718581
The sponsor
Hutchmed has completed 74 of 86 trials tracked globally, with 12 terminated, and separately runs a 127-trial portfolio spanning completed, recruiting, and active programs. Within the -tumor family specifically, the company has an 81% completion rate across 16 trials, a track record consistent with typical sponsor execution rather than a warning sign. The new study is the sponsor's first active trial for this specific asset, alongside no terminated prior programs for HMPL-A830. NCT07718581HMPL-A830 in Solid TumorsNCT07718581
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.